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aCGH

:   array‐based comparative genomic hybridization

cCCC

:   cervical clear cell carcinoma

DES

:   diethylstilbestrol

FFPE

:   formalin‐fixed paraffin‐embedded

HPV

:   human papillomavirus

IHC

:   immunohistochemical

LOH

:   loss of heterozygosity

MBOC

:   Matrigel bilayer organoid culture

NGS

:   next‐generation sequencing

oHGSC

:   ovarian high‐grade SC organoid

PDC

:   patient‐derived cell

pERK

:   phosphorylated ERK

SC

:   serous carcinoma

SNV

:   single nucleotide variant

VAF

:   variant allele frequency.

1. INTRODUCTION {#cas14119-sec-0001}
===============

Cervical cancer has been a global threat to women\'s health. More than two‐thirds of cervical cancers are classified as squamous cell carcinoma,[1](#cas14119-bib-0001){ref-type="ref"}, [2](#cas14119-bib-0002){ref-type="ref"}, [3](#cas14119-bib-0003){ref-type="ref"} which is currently decreasing owing to intensive cervical screening and vaccination against HPV. The remainder are predominantly adenocarcinoma, which is on the rise worldwide, requiring prompt and practical measures against this disease. Cervical clear cell carcinoma is an extremely rare subtype of adenocarcinoma. It is histologically characterized by clear cytoplasm of cancer cells, closely resembling the features of its ovarian counterpart.[4](#cas14119-bib-0004){ref-type="ref"} Due to the small number of cases, epidemiological, clinical, and pathological features of cCCC have remained largely unknown.[5](#cas14119-bib-0005){ref-type="ref"}, [6](#cas14119-bib-0006){ref-type="ref"}, [7](#cas14119-bib-0007){ref-type="ref"}, [8](#cas14119-bib-0008){ref-type="ref"}, [9](#cas14119-bib-0009){ref-type="ref"} Limited information thus far reported includes that patients with cCCC at an advanced stage had poor prognosis,[10](#cas14119-bib-0010){ref-type="ref"} and that in utero exposure to the antimiscarriage drug DES and HPV infection might be implicated in its pathogenesis.[11](#cas14119-bib-0011){ref-type="ref"}, [12](#cas14119-bib-0012){ref-type="ref"}, [13](#cas14119-bib-0013){ref-type="ref"}, [14](#cas14119-bib-0014){ref-type="ref"} There are virtually no resources available for cCCC research either, such as genetically engineered mouse models, PDCs, or patient‐derived xenografts. These situations make it yet more difficult to undertake research on cCCC.

Organoid culture is an emerging technique that enables infinite expansion of murine and human normal stem cells.[15](#cas14119-bib-0015){ref-type="ref"}, [16](#cas14119-bib-0016){ref-type="ref"} To date, it has been applied to various research fields, including infectious disease models,[17](#cas14119-bib-0017){ref-type="ref"} developmental biology,[18](#cas14119-bib-0018){ref-type="ref"} and epithelial regeneration.[19](#cas14119-bib-0019){ref-type="ref"} We also reported the establishment of murine organoid‐based carcinogenesis models for intestine,[20](#cas14119-bib-0020){ref-type="ref"} lung,[21](#cas14119-bib-0021){ref-type="ref"} hepatobiliary tract,[22](#cas14119-bib-0022){ref-type="ref"} and pancreas.[23](#cas14119-bib-0023){ref-type="ref"} These organoid culture techniques have now become common for patient‐derived samples from diverse types of cancer, which revealed that tumor‐derived organoids basically retained the morphology and genetic aberrations of the original tumors.[24](#cas14119-bib-0024){ref-type="ref"}, [25](#cas14119-bib-0025){ref-type="ref"}, [26](#cas14119-bib-0026){ref-type="ref"} Although its validity in gynecologic tumors has long remained elusive,[27](#cas14119-bib-0027){ref-type="ref"} we recently established an efficient culture method optimized for ovarian and endometrial tumors,[28](#cas14119-bib-0028){ref-type="ref"} by modification of an MBOC protocol that we initially developed for a murine carcinogenesis model ex vivo.[29](#cas14119-bib-0029){ref-type="ref"} ^.^

In an effort to systematically collect various gynecologic tumors as PDC, we experienced a case of cCCC. Based on its scarcity, we dared to undertake its organoid culture using our new modified protocol, although we had never cultured primary cervical adenocarcinoma before. In this study, we successfully propagated and characterized tumor‐derived organoids, establishing a novel cell line that basically retained the features of the original tumor. This PDC will likely provide mechanistic insights into cCCC and serve as a promising resource for preclinical studies.

2. MATERIALS AND METHODS {#cas14119-sec-0002}
========================

2.1. Patient information {#cas14119-sec-0003}
------------------------

This study was approved by the Ethics Committee of Chiba Cancer Center (Chiba, Japan) with Institutional Review Board approval number H28‐J158. Written informed consent was obtained from the patient. The detailed clinical information will be submitted elsewhere as a case report (K. Ebisawa, M. Ijiri, K. Suzuka, T. Sugiyama, M. Itami, N. Tanaka, unpublished data.). Briefly, the patient was a 23‐year‐old woman without infection with the 13 strains of high‐risk HPVs. Radical hysterectomy with bilateral adnexectomy and pelvic lymphadenectomy were carried out for the cervical tumor. The resected tumor was histologically diagnosed with pT1b2N0M0. The patient was treated with adjuvant chemotherapy by irinotecan hydrochloride and nedaplatin. No obvious signs of recurrence have been detected at our outpatient department for 6 months after surgery.

2.2. Isolation of tumor cells and primary organoid culture {#cas14119-sec-0004}
----------------------------------------------------------

The biopsy samples were minced and dissociated into small clusters or single cells by digesting with 2 U/mL dispase II, 1 mg/mL collagenase P (Roche Diagnostics, Tokyo, Japan) and Accumax (Innovative Cell Technologies, San Diego, CA, USA). The resuspended cells were plated on solidified Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). The following morning, viable cells attached to Matrigel were covered with Matrigel and overlaid with media to start the organoid culture. To increase the yield of tumor cells, we further carried out digestion of floating tissue fragments and cell aggregates by Accumax treatment and then undertook organoid culture. Primary organoid culture was carried out according to the modified MBOC protocol as previously described[28](#cas14119-bib-0028){ref-type="ref"} and in [Data S1](#cas14119-sup-0002){ref-type="supplementary-material"}.

2.3. Pathological analysis {#cas14119-sec-0005}
--------------------------

Organoids obtained by depolymerization of Matrigel with Cell Recovery Solution (BD Biosciences) were resuspended in iPGell (GenoStaff, Tokyo, Japan). The iPGell‐embedded organoids or resected tumors were fixed in 10%‐15% buffered neutral formalin, dehydrated, and embedded in paraffin. The detailed methods are described in [Data S1](#cas14119-sup-0002){ref-type="supplementary-material"}.

2.4. Genomic DNA analysis {#cas14119-sec-0006}
-------------------------

NucleoSpin Tissue (Takara, Shiga, Japan) and a QIAmp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) were used for extraction of genomic DNA from organoids and FFPE samples of tumor and normal tissues, respectively, and subjected to NGS analysis as previously described,[30](#cas14119-bib-0030){ref-type="ref"} and aCGH analysis. The detailed methods are described in [Data S1](#cas14119-sup-0002){ref-type="supplementary-material"}.

2.5. Tumorigenicity assay {#cas14119-sec-0007}
-------------------------

Immunodeficient nude mice BALB/cA^nu/nu^ were purchased from CLEA Japan (Tokyo, Japan). Animal studies were carried out with the approval of the Chiba Cancer Center for Ethics in Animal Experimentation. Tumor‐derived organoids corresponding to 5 × 10^5^ cells were resuspended in 100 μL advanced DMEM/F12 mixed with 100 μL Matrigel at a 1:1 ratio and inoculated into one side of the dorsal skin of nude mice. Tumor development was monitored for 3 months.

2.6. Cell proliferation and drug sensitivity assay {#cas14119-sec-0008}
--------------------------------------------------

For in vitro assay, organoids were collected and dissociated into single cells by digesting with Accumax. The dissociated cells were counted using a TC20 Automated Cell Counter (Bio‐Rad, Hercules, CA, USA). For cell proliferation assays, 2 × 10^4^ single cells/well were plated in a 24‐well plate with solidified Matrigel to form organoids, or an ultra‐low attachment 24‐well plate to generate spheroids. Cell viability was analyzed with CellTiter‐Glo3D Cell Viability Assay (Promega, Fitchburg, WI, USA) at 5 time points (day 0, 3, 7, 10, and 14) in triplicate, and the results were normalized to the values on day 0. For the drug sensitivity assay, 5 × 10^3^ single cells/well were plated into PrimeSurface 96U (Sumitomo Bakelite, Tokyo, Japan) in triplicate. At 48 hours after plating, paclitaxel (Wako, Osaka, Japan), cisplatin (Wako), gemcitabine hydrochloride (Wako), crizotinib (Tocris Bioscience, Bristol, UK), and SU11274 (Cayman Chemical, Ann Arbor, MI, USA) were dispensed at 5 serially diluted doses from 5 to 100 nmol/L, from 1 to 100 μmol/L, from 1 to 100 nmol/L, from 100 nmol/L to 10 μmol/L and, from 100 nmol/L to 10 μmol/L, respectively, and analyzed in triplicate following 96 hours of drug incubation. The mean ± SD of the results from 3 independent experiments is shown for each drug.

3. RESULTS {#cas14119-sec-0009}
==========

3.1. Propagation of organoids from a cervical biopsy sample of CCC {#cas14119-sec-0010}
------------------------------------------------------------------

In order to expand patient‐derived organoids of cCCC, we obtained a biopsy sample (Figure [1](#cas14119-fig-0001){ref-type="fig"}A) from a female patient diagnosed with cCCC. We first evaluated one‐third of the samples by histological analysis and confirmed that cancer cells manifested nuclear atypia and clear cytoplasm, consistent with general features of CCC (Figure [1](#cas14119-fig-0001){ref-type="fig"}B). The rest were subjected to primary organoid culture with the modified MBOC protocol.[28](#cas14119-bib-0028){ref-type="ref"} Following dissemination on solidified Matrigel and with serum‐free organoid culture media, organoids readily formed small or large solid structures with multiple budding, which was sustained after embedding in Matrigel and over serial passages (Figure [1](#cas14119-fig-0001){ref-type="fig"}C). We also confirmed that cCCC‐derived organoids could be propagated for at least 6 months, tolerated a cycle of freeze and thaw, and proliferated as a monolayer for at least 2 months in the absence of Matrigel (Figure [1](#cas14119-fig-0001){ref-type="fig"}C).

![Stable propagation of cervical clear cell carcinoma‐derived organoids by modified Matrigel bilayer organoid culture. A, Biopsy sample collected from the cervical tumor. Scale bar = 10 mm. B, H&E staining of biopsy sample. Scale bar = 50 μm. Inset shows a magnified image. C, Upper panels, representative time‐lapse images of tumor‐derived organoids (OR) in the bright field (passage \[P\]0) at 1‐7 d. Lower panels, organoids after P1 and P7 and recovered from a cryopreserved sample. Adherent cells growing in monolayer are also shown. Scale bar = 200 μm. Insets show magnified images. D, Pathological examination of organoids (left) and organoid‐derived adherent cells (middle). Upper panels, H&E staining. Lower panels, Papanicolaou staining. Cervical cytological specimens are shown as a reference (right). Scale bar = 50 μm](CAS-110-2992-g001){#cas14119-fig-0001}

To examine to what extent propagated organoids retained the features of the original tumor, we histologically compared organoids and the biopsy specimen by H&E staining of FFPE sample‐derived thin sections. Organoids exclusively consisted of atypical cells with clear cytoplasm (Figure [1](#cas14119-fig-0001){ref-type="fig"}D), concordant with morphological features of the original tumor (Figure [1](#cas14119-fig-0001){ref-type="fig"}B). Similar results were obtained for monolayer cells (Figure [1](#cas14119-fig-0001){ref-type="fig"}D). We also made a comparison by using Papanicolaou staining, a routine procedure in cytological examination. Again, we confirmed that cells within organoids and in monolayer resembled the original malignant cells detected in cervical cytological specimens for the initial diagnosis (Figure [1](#cas14119-fig-0001){ref-type="fig"}D).

3.2. Retention of histological features of CCC component, but not SC component, in biopsy‐derived organoids {#cas14119-sec-0011}
-----------------------------------------------------------------------------------------------------------

While we were characterizing the biopsy‐derived organoids, the patient underwent surgery. The cervical tumor with exophytic papillary growth was resected*,* which was as large as 5.0 cm × 3.0 cm × 4.0 cm (Figure [2](#cas14119-fig-0002){ref-type="fig"}A). The tumor showed papillary structures with fibrous stalks (Figure [2](#cas14119-fig-0002){ref-type="fig"}B). Intriguingly, the lesion at the peripheral tip, comprising 5% of the tumor, showed histological features quite distinct from the rest (Figure [2](#cas14119-fig-0002){ref-type="fig"}B). High‐magnification observation revealed that the majority of cancer cells showed nuclear enlargement, irregular nuclei, and clear cytoplasm, consistent with the diagnosis of CCC (Figure [2](#cas14119-fig-0002){ref-type="fig"}C) and the histological features of the biopsy sample (Figure [1](#cas14119-fig-0001){ref-type="fig"}B). However, the minor fraction proved to be SC, another rare subtype of cervical adenocarcinoma (Figure [2](#cas14119-fig-0002){ref-type="fig"}C).

![Histological characterization of the tumor with clear cell carcinoma (CCC) and serous carcinoma (SC) components. A, Macroscopic view of a resected cervical tumor (arrowheads) at the bottom of the uterus. B, Whole slide images of the cervical tumor stained with H&E. Upper panel, thin section of tumor homogeneously occupied by papillary growing CCC. Lower panel, thin section of tumor with mixed histology. CCC component was placed in the proximal part; SC component occupied peripheral lesions (circles). Inset shows a macroscopic view of the corresponding part of the formalin‐fixed tumor. Scale bar = 5 mm. C, Histological examination by H&E and immunohistochemical staining. Left, biopsy‐derived organoids. Middle, CCC component of the tumor. Right, SC component of the tumor. An inset for p53 staining in CCC shows the result of staining in normal cervical mucosa as a reference. Scale bar = 50 μm](CAS-110-2992-g002){#cas14119-fig-0002}

To verify that the biopsy‐derived organoids indeed derived from the CCC component of the original tumor, we set out to undertake IHC analysis. We selected multiple markers widely used to distinguish between CCC and SC.[31](#cas14119-bib-0031){ref-type="ref"} Specifically, HNF1‐β, Napsin A, ARID1A, and p53 were evaluated. The CCC cells of the original tumor were positive for HNF‐1β as predicted, but also positive for ARID1A and negative for Napsin A, unlike typical ovarian CCC. Accumulation of p53 was evident in CCC, but its expression level varied within the CCC area (Figure [2](#cas14119-fig-0002){ref-type="fig"}C). These results suggest that this cCCC case might be only partially similar to typical ovarian CCC in terms of histological features. In contrast, SC cells of the original tumor showed strongly positive for p53 and ARID1A, but not for HNF‐1β, or Napsin A, compatible with the typical phenotype of ovarian SC (Figure [2](#cas14119-fig-0002){ref-type="fig"}C). We also confirmed that both organoids and the original tumor had high expression of Ki‐67, indicative of active proliferation (Figure [2](#cas14119-fig-0002){ref-type="fig"}C). Collectively, these observations suggested that the organoids were likely derived from the CCC component, but not from the SC component.

3.3. Retention of original CCC histological features in organoid‐derived xenograft {#cas14119-sec-0012}
----------------------------------------------------------------------------------

To further verify the CCC origin of the biopsy‐derived organoids, we inoculated the organoids at passage 3 (Figure [3](#cas14119-fig-0003){ref-type="fig"}A) into the bilateral dorsal skin of nude mice. Initially, it appeared that a palpable tumor developed only on the right side (Figure [3](#cas14119-fig-0003){ref-type="fig"}B). However, a tiny nodule on the left side was later found at the time of death (Figure [3](#cas14119-fig-0003){ref-type="fig"}C). The cut surface of the right tumor indicated that it had indeed a solid nature (Figure [3](#cas14119-fig-0003){ref-type="fig"}D). Microscopic analysis by H&E staining revealed that both the nodules contained papillary and solid fractions (Figure [3](#cas14119-fig-0003){ref-type="fig"}E). Precise histological evaluation showed that both nodules were predominantly composed of cancer cells with nuclear atypia and clear cytoplasm (Figure [3](#cas14119-fig-0003){ref-type="fig"}F), strongly resembling the histological properties of the organoids and the original CCC (Figure [2](#cas14119-fig-0002){ref-type="fig"}C). Immunohistochemical analysis also indicated that protein expression profiles in both nodules were significantly similar, including positive findings in HNF1‐β, p53, and Ki‐67 (Figure [3](#cas14119-fig-0003){ref-type="fig"}F). Based on these findings, we concluded that the organoids were highly likely to consist of a pure cCCC population and retain the original features of the tumor. The right s.c. tumor was recovered as cCCC organoids, which remained almost the same in morphology to those before inoculation (Figure [3](#cas14119-fig-0003){ref-type="fig"}G). To confirm the reproducibility of the xenograft development from organoids, we tried inoculation of organoids again at passage 7. However, no s.c. tumor developed, even after 3 months. These observations suggest that the biopsy‐derived CCC organoids might have only low tumorigenic potential, which was further lowered during culture by unknown mechanisms.

![Development of xenograft from cervical clear cell carcinoma organoids. A, Bright field image of organoids before inoculation in nude mice (passage \[P\]3). Scale bar = 200 μm. Inset shows a magnified image. B, Palpable tumor development in nude mice. Mice were killed 76 days after duplicate inoculation of tumor organoids on both left (L) and right (R). Left image, whole body image from the back. A solid tumor was evident only on the right side (arrowheads). Right image, lateral view of the tumor. The tumor consisted of multiple nodules (circle). Scale bar = 10 mm. C, Isolated tumors. Upper panel, macroscopic views of the tumors on both sides (circle) during dissection. Lower panel, isolated tumors. Scale bar = 10 mm. D, Slices of tumor after formalin fixation. Scale bar = 10 mm. E, Whole slide images of the right tumor and left nodule stained with H&E. Right solid tumor was sliced into 3 pieces. The 2 boxes show areas magnified in (F). Scale bar = 5 mm. F, Comparison of histopathological features between left tiny nodule and right solid tumor by H&E and immunohistochemical staining against HNF‐1β, Napsin A, p53, ARID1A, and Ki‐67. Scale bar = 50 μm. G, Bright field image of s.c. tumor‐derived organoids (P4). Inset shows a magnified view. Scale bar = 200 μm](CAS-110-2992-g003){#cas14119-fig-0003}

3.4. Retention of original CCC genetic aberrations and heterogeneity in biopsy‐derived organoids {#cas14119-sec-0013}
------------------------------------------------------------------------------------------------

In many types of cancers, it has been reported that tumor‐derived organoids basically retained the majority of somatic mutations, copy number variations, and intratumoral heterogeneity observed in the original tumors.[32](#cas14119-bib-0032){ref-type="ref"}, [33](#cas14119-bib-0033){ref-type="ref"}, [34](#cas14119-bib-0034){ref-type="ref"} To verify this notion in this case, we compared the biopsy‐derived organoids and FFPE samples of the original tumor\'s CCC component at the genome level, by targeted sequencing analysis of 409 cancer‐related genes. Organoids and original CCC harbored only 4 and 3 mutations, respectively, of which 2 mutations were shared in common (Figure [4](#cas14119-fig-0004){ref-type="fig"}A). These was a nonsynonymous mutation in *MLH1* and a synonymous mutation in *TFE3*. The VAF for *TFE3* was 37% in organoids and 49% in the original CCC (Figure [4](#cas14119-fig-0004){ref-type="fig"}A). Being a synonymous mutation, it is unlikely that the *TFE3* mutation was positively selected among cancer cells during culture. In addition, VAF of the *TFE3* mutation was almost 50% in organoids, strongly suggesting that cancer cells in the tumor might purely consist of heterozygous mutant cells, which selectively propagated as organoids, leading to a 1.32‐fold enrichment of cancer cells. The VAF for the *MLH1* mutation increased by 1.37‐fold from 30% in CCC to 41% in organoids (Figure [4](#cas14119-fig-0004){ref-type="fig"}A), suggestive of a similar magnitude of enrichment of cancer cells. The VAF of the mutant allele at 41% theoretically predicts that heterozygous mutant cells and WT cells would comprise 82% and 18%, respectively, indicative of the heterogeneity in organoids.

![Mutation profiles of cancer‐related genes in biopsy‐derived organoids and the resected original tumor. A, Mutation profiles by target sequence analysis. Left, a list of somatic mutations in clear cell carcinoma (CCC) component (formalin‐fixed paraffin‐embedded \[FFPE\]) and biopsy‐derived organoids (OR). N, nonsynonymous mutation; S, synonymous mutation. Right, Venn diagram of somatic mutations in CCC and serous carcinoma (SC) component and biopsy‐derived organoids. The numbers in parentheses indicate the number of synonymous mutations. B, Estimation of copy number alterations based on depth of coverage obtained using targeted sequencing of 409 cancer‐related genes. Focal amplification at the *MET* locus was implied in organoids and CCC component of the tumor. C, Validation of an SC component‐specific in‐frame 3‐base deletion (box) in the *TP53* gene (c.754_756del CTC) by Sanger sequencing. D, Validation of a germ‐line heterozygous single nucleotide variant in the *TP53* gene (c.215 C\>G) (arrowheads) by Sanger sequencing. VAF, variant allele frequency](CAS-110-2992-g004){#cas14119-fig-0004}

In contrast, the original SC harbored a large number of mutations. However, no shared mutations with organoids or the CCC component were identified, unequivocally revealing their distinct natures (Figure [4](#cas14119-fig-0004){ref-type="fig"}A). Notably, the SC component harbored multiple nonsynonymous mutations in DNA repair‐related genes, including *PARP1, FANCD2*, and *PMS2* ([Table S1](#cas14119-sup-0002){ref-type="supplementary-material"}). Hence, it is possible that defects in DNA repair underlie the observed mutator phenotype in the original SC. Based on the NGS data, we also estimated genome‐wide copy number changes in these samples. Although the signal to noise ratio of the data was relatively low, it seemed likely that the copy number gain in *MET* and the genome‐wide copy number changes were shared by organoids and the original CCC, but not by the original SC (Figure [4](#cas14119-fig-0004){ref-type="fig"}B).

3.5. Serous carcinoma‐specific microdeletion and biallelic inactivation of *TP53* {#cas14119-sec-0014}
---------------------------------------------------------------------------------

It has been well established that *TP53* is almost invariably mutated in ovarian high‐grade SC.[35](#cas14119-bib-0035){ref-type="ref"} Together with the observation that p53 was accumulated in the original SC, and to a lesser extent in the original CCC (Figure [2](#cas14119-fig-0002){ref-type="fig"}C), we assumed that the tumor would likely harbor a *TP53* mutation. However, NGS analysis did not uncover point mutations in *TP53*. We then carefully examined the raw NGS data for the *TP53* gene, and found a 3‐bp in‐frame deletion (c.754_756 del CTC) exclusively in SC (Figure [4](#cas14119-fig-0004){ref-type="fig"}C), which could result in p53 accumulation in tumors.[36](#cas14119-bib-0036){ref-type="ref"} Interestingly, we found a heterozygous SNV at c.215 (C \> G), which results in amino acid substitution from Pro to Arg at codon 72 (Figure [4](#cas14119-fig-0004){ref-type="fig"}D). This particular situation allowed us to distinguish between the 2 alleles of *TP53*. The VAF of the WT allele at this nucleotide was approximately 50% in all the samples except for 10% in the SC component. As a tumor suppressor frequently inactivated by LOH, we predicted the presence of *TP53* LOH in SC, but it was difficult to confirm 1 copy loss from the putative copy number inferred from the NGS data.

We then set out to accurately measure copy number alterations by aCGH analysis. The FFPE samples of CCC organoid‐derived xenograft and the tumor\'s CCC and SC components were compared. The copy number alterations of the xenograft were similar to those of the original CCC, with further accumulation of alterations in xenograft (Figure [5](#cas14119-fig-0005){ref-type="fig"}A). Specifically, we found chromosomal gain at 8 and 22, and loss at 13, 18, and 21 in common. In sharp contrast, the genomic copy number of SC was significantly altered. As predicted, 1 copy loss of *TP53*, along with whole chromosome 17p, was observed in SC (Figure [5](#cas14119-fig-0005){ref-type="fig"}A).

![Retention of copy number alterations of original cervical clear cell carcinoma in organoid‐derived (CCC‐OR) xenograft. A, Copy number alterations of the original cervical tumor and organoid‐derived xenograft. Formalin‐fixed paraffin‐embedded samples were analyzed. Focal copy number gain of *MET* in organoid‐derived xenograft and CCC component of the tumor were detected. Serous carcinoma (SC) component showed extensive genomic instability, including a copy number loss of *TP53*. B, Immunohistochemical staining of MET, phosphorylated (p)ERK, and pAKT. Scale bar = 50 μm](CAS-110-2992-g005){#cas14119-fig-0005}

3.6. Clear cell carcinoma‐specific overexpression of MET {#cas14119-sec-0015}
--------------------------------------------------------

Copy number gain of *MET* in CCC and xenograft, but not in SC, was also confirmed by aCGH (Figure [5](#cas14119-fig-0005){ref-type="fig"}A). To investigate whether and in what proportion MET is overexpressed, we undertook IHC staining. Membranous staining of MET was observed in the CCC, organoids, and xenograft, but not SC or normal cervix (Figure [5](#cas14119-fig-0005){ref-type="fig"}B). Notably, *MET* overexpression was unanimously observed in these CCC‐related samples, suggesting its critical roles in CCC development. As MEK/ERK and PI3K/AKT pathways are the major pathways downstream of MET, we further analyzed the status of AKT and ERK by IHC staining. There were pERK‐positive cells in CCC‐related samples, but the majority of cells with *MET* overexpression were not positive for pERK (Figure [5](#cas14119-fig-0005){ref-type="fig"}B). On the contrary, SC rather contained more pERK‐positive cells than did CCC despite *MET* overexpression. Moreover, pAKT was not detected in either SC or CCC‐related samples (Figure [5](#cas14119-fig-0005){ref-type="fig"}B). These results suggest that MET might exert its pro‐oncogenic effects through noncanonical pathways in this CCC case.

3.7. Drug sensitivity of cCCC organoid‐derived spheroids for anticancer drugs {#cas14119-sec-0016}
-----------------------------------------------------------------------------

For high‐throughput drug screening, Matrigel‐based organoids might not be ideal, as time‐consuming and complicated procedures are usually required. Practically, spheroids and adherent cells are more favored. In this regard, we previously confirmed that organoids from ovarian and endometrial tumors could generally be turned into spheroids, and used for drug‐sensitivity assay.[28](#cas14119-bib-0028){ref-type="ref"} In a similar manner, we dissociated cCCC organoids into single cells and split them into organoid and spheroid cultures. Cells readily aggregated and developed large spheroids, in a comparable way to organoids in Matrigel (Figure [6](#cas14119-fig-0006){ref-type="fig"}A). We noted that organoids and spheroids proliferated comparably at least for 1 week from the beginning of the culture (Figure [6](#cas14119-fig-0006){ref-type="fig"}B). Based on these observations, we reasoned that spheroid‐based drug sensitivity assay would mimic similar responses to organoids, if carried out within 7 days. We then treated cCCC organoids with anticancer drugs commonly used in clinic for gynecological cancer. The IC~50~ values for paclitaxel and cisplatin were 20 nmol/L and 19 μmol/L, respectively (Figure [6](#cas14119-fig-0006){ref-type="fig"}C), which were comparable to IC~50~ values of ovarian cancer organoids for paclitaxel (10‐100 nmol/L) and cisplatin (10‐100 μmol/L), respectively.[28](#cas14119-bib-0028){ref-type="ref"} The IC~50~ value for gemcitabine was 37 nmol/L, which was comparable to that of pancreatic cancer organoids (1‐100 nmol/L).[37](#cas14119-bib-0037){ref-type="ref"} Given that ovarian and pancreatic cancers are relatively sensitive to these agents, cCCC organoids would be likely sensitive to these drugs as well.

![Proliferative capacity and drug sensitivity of a cervical clear cell carcinoma (cCCC)‐derived cell line. A, Representative time‐lapse images of organoids and spheroids at 3‐14 d. Scale bar = 200 μm. B, Comparison of proliferative capacity between Matrigel‐based organoid culture and spheroid culture using a cCCC‐derived organoid line. C, Dose response curves for organoid‐derived spheroids treated with paclitaxel, cisplatin, and gemcitabine. Mean ± SD of results from 3 independent experiments is shown for each drug. D, Left, gene copy number in chromosome 7 of the cCCC organoids (OR) and ovarian high‐grade serous carcinoma (oHGSC) organoids based on the coverage in next‐generation sequencing analysis. *MET* amplification is present on cCCC, but not in oHGSC. Right, dose response curves for MET inhibitors crizotinib and SU11274. Mean ± SD of results from 3 independent experiments is shown for each drug](CAS-110-2992-g006){#cas14119-fig-0006}

With amplification of the *MET* gene, we speculated that cCCC organoids would be sensitive to crizotinib, a clinically approved MET inhibitor, owing to a mechanism known as "oncogene addiction". We included oHGSC that we recently established[28](#cas14119-bib-0028){ref-type="ref"} as a negative control without *MET* amplification (Figure [6](#cas14119-fig-0006){ref-type="fig"}D), and investigated responses of these 2 organoids to crizotinib. Although cCCC organoids appeared to respond better than oHGSC organoids in the range of \<1 μmol/L, IC~50~ values of cCCC and oHGSC organoids were largely similar, with 2.2 μmol/L and 1.3 μmol/L, respectively (Figure [6](#cas14119-fig-0006){ref-type="fig"}D). As crizotinib potently inhibits not only MET but also anaplastic lymphoma kinase, we reasoned that observed marginal difference in drug sensitivity might be attributable to anaplastic lymphoma kinase inhibition by crizotinib. We therefore tested SU11274, a specific MET inhibitor. The IC~50~ values of cCCC and oHGSC were 1.7 μmol/L and \>10 μmol/L, respectively (Figure [6](#cas14119-fig-0006){ref-type="fig"}D). Considering that IC~50~ values of ES2 and RMG1, ovarian CCC cell lines with *MET* overexpression, were 5 μmol/L and 3 μmol/L, respectively,[38](#cas14119-bib-0038){ref-type="ref"} it is likely that the cCCC organoids are sensitive to SU11274, and thereby suggestive of addiction to MET.

4. DISCUSSION {#cas14119-sec-0017}
=============

In this study, we newly established a cell line from primary cCCC by organoid culture. Through detailed analyses of organoids and the original tumor, we confirmed that this PDC retained many features of the original cCCC, and can be subjected to drug screening in vitro as spheroids, and potentially in vivo as xenografts. We therefore designated the cell line as YMC7 for future distribution in the research community. To the best of our knowledge, this is the first successful case of organoid culture of primary cervical adenocarcinoma, let alone cCCC. As an adherent cell line, only 1 case of cCCC was documented some 30 years ago.[39](#cas14119-bib-0039){ref-type="ref"} Whereas this cell line with high tumorigenic potential was established from cancerous ascites of a dead patient, YMC7 derives from a resectable primary tumor in a young patient and shows low tumorigenic potential. Consequently, it could help investigations on the mechanisms underlying the early phase of carcinogenesis of cCCC, and recapitulation of tumor progression by gene transduction into organoids. Given the low number of studies with cCCC, we referred to studies in ovarian CCC,[40](#cas14119-bib-0040){ref-type="ref"}, [41](#cas14119-bib-0041){ref-type="ref"} which is the second most common ovarian epithelial cancer in Japan.[1](#cas14119-bib-0001){ref-type="ref"} For example, chromosomal gains and losses identified in cCCC resembled those of ovarian CCC previously documented.[42](#cas14119-bib-0042){ref-type="ref"} In addition, copy number gain of *MET* and protein overexpression of MET in cCCC were previously documented in ovarian CCC.[43](#cas14119-bib-0043){ref-type="ref"}, [44](#cas14119-bib-0044){ref-type="ref"} These findings suggest that the mechanisms underlying carcinogenesis of cCCC might be highly correlated with those of ovarian CCC. As predicted, pharmacological MET inhibition potently impaired the growth of cCCC cells, suggesting that the *MET* gene might have potential as a therapeutic target in case of recurrence of this cCCC.

Without an episode of DES exposure in utero or infection with high‐risk HPV, this case might not be typical of cCCC of the young. Although the mechanisms underlying tumor development in this case remain largely unknown, there were some findings that could possibly account for such unusual onset. First, there was a somatic mutation in *MLH1* in this case. Lynch syndrome‐related cCCC[8](#cas14119-bib-0008){ref-type="ref"} and POLE‐mutated cCCC[9](#cas14119-bib-0009){ref-type="ref"} have been previously documented, in which mismatch repair genes including *MLH1* were commonly affected, leading to a mutator phenotype in these diseases. However, only a few mutations were identified in this cCCC case, suggesting that the *MLH1* mutation might not be relevant in carcinogenesis or could exert protumorigenic effects by unknown mechanisms. Second, early onset and low mutational burdens rather suggested that a fusion gene might underlie the carcinogenesis in this case. Hence, its exploration by RNA sequencing might be warranted. Finally, a heterozygous SNV in the *TP53* gene that gives rise to codon 72 polymorphisms (Pro \> Arg) was identified. As one of the common polymorphisms (rs1042522), it is under intensive investigation.[45](#cas14119-bib-0045){ref-type="ref"} It has been reported that this polymorphism increased the risk of cancer in Asian and African Americans[46](#cas14119-bib-0046){ref-type="ref"} and is more susceptible to degradation by the HPV 18 E6 protein,[47](#cas14119-bib-0047){ref-type="ref"} raising the possibility that gynecological cancer in Japanese patients might be promoted by this polymorphism. However, it was shown that Arg72 variant p53 could induce apoptosis more efficiently than Pro72 variant p53.[48](#cas14119-bib-0048){ref-type="ref"} As seen above, there are many inconsistencies on the functional roles of codon 72 polymorphisms of p53 across cancer types and ethnicities,[45](#cas14119-bib-0045){ref-type="ref"} it makes it difficult to determine its exact roles. In this study, accumulation of p53 was observed in CCC but not in normal cervical mucosa, although they had the same genotype for *TP53*. It is tempting to speculate that this heterozygous SNV itself might not directly induce dysfunction of p53, but can cooperate with some cancer‐related mutations, which is to be investigated further.

Another unusual aspect of this cCCC case is that it also contained a fraction of SC, another rare subtype of cervical adenocarcinoma. Both genomic and histological analyses clearly indicated the distinct nature of SC and CCC in the original tumor, strongly suggesting that they might have developed independently. However, intratumoral localization of the SC component was distal to the CCC component without direct connection with cervical tissue, rather suggesting its derivation from CCC in this case. It is well known that the *TP53* gene is frequently mutated in ovarian high‐grade SC[35](#cas14119-bib-0035){ref-type="ref"} and endometrial SC.[49](#cas14119-bib-0049){ref-type="ref"} In this study, we also identified a 3‐bp in‐frame deletion and LOH in the *TP53* gene in the SC component of the tumor. Accumulation of p53 was also observed, consistent with the same 3‐bp deletion in ovarian SC.[36](#cas14119-bib-0036){ref-type="ref"} These observations suggest that aberration of the *TP53* gene might be implicated in the carcinogenesis of cervical SC as well. Based on these findings, we now propose possible mechanisms underlying the development of this case with mixed‐type cervical adenocarcinoma (Figure [7](#cas14119-fig-0007){ref-type="fig"}). In this model, CCC first occurred from cervical tissue of a patient with a heterozygous SNV in *TP53* genes. The *MLH1* gene was then mutated in a population that expanded to more than two‐thirds of CCC cells. However, 3‐bp deletion and LOH of the *TP53* gene occurred in a fraction of CCC cells without mutated *MLH1*, and subsequently transformed into SC cells. The copy number gain of *MET* occurred in only CCC cells, although its timing remains undetermined. Another possibility is that both components occurred from distinct lesions of normal cervical epithelia in a completely independent manner, which is known as a collision tumor, although it is relatively rare in gynecological tumors.[50](#cas14119-bib-0050){ref-type="ref"}

![Possible mechanisms underlying the development of cervical adenocarcinoma with clear cell carcinoma (CCC) and serous carcinoma (SC) components. A putative model for bidirectional carcinogenesis of the cervix in this study. SC sequentially developed from a CCC‐related common precursor. In this model, the timing of *MET* copy number gain remains elusive. Alternatively, it is also possible that the 2 components independently developed as a collision tumor, although its probability might not be high. LOH, loss of heterozygosity; mut, mutant; OR, organoid; SNV, single nucleotide variant](CAS-110-2992-g007){#cas14119-fig-0007}

In conclusion, we established a novel cell line of an extremely rare gynecological cancer. This cell line will not only contribute to elucidation of its pathogenesis, but also provide a preclinical model for drug discovery, accelerating both basic and translational research in gynecological cancer.
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